See more : Aeon Co., Ltd. (AONNY) Income Statement Analysis – Financial Results
Complete financial analysis of Cartesian Therapeutics, Inc. (RNAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cartesian Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Peptron, Inc. (087010.KQ) Income Statement Analysis – Financial Results
- Counter Press Acquisition Corporation (CPAQW) Income Statement Analysis – Financial Results
- Tanger Inc. (SKT) Income Statement Analysis – Financial Results
- Thryv Holdings, Inc. (THRY) Income Statement Analysis – Financial Results
- HEICO Corporation (HEI-A) Income Statement Analysis – Financial Results
Cartesian Therapeutics, Inc. (RNAC)
About Cartesian Therapeutics, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.00M | 110.78M | 85.08M | 16.60M | 6.68M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Cost of Revenue | 1.55M | 2.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 24.45M | 108.74M | 85.08M | 16.60M | 6.68M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Gross Profit Ratio | 94.03% | 98.16% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 71.84M | 72.38M | 68.74M | 54.51M | 42.74M | 47.69M | 45.17M | 29.70M | 22.98M | 10.49M |
| General & Administrative | 40.58M | 23.86M | 20.94M | 18.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.95M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.58M | 23.86M | 20.94M | 18.91M | 14.36M | 17.26M | 18.08M | 12.25M | 7.29M | 7.95M |
| Other Expenses | 0.00 | 330.00K | 15.00K | 89.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 110.87M | 96.24M | 89.67M | 73.42M | 57.11M | 64.95M | 63.24M | 41.95M | 30.27M | 18.44M |
| Cost & Expenses | 112.42M | 96.24M | 89.67M | 73.42M | 59.13M | 65.93M | 63.99M | 42.75M | 31.32M | 18.44M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 834.00K | 1.05M | 617.00K | 234.00K | 171.00K | 111.00K |
| Interest Expense | 2.83M | 3.03M | 2.84M | 1.56M | 1.52M | 1.49M | 1.21M | 1.25M | 948.00K | 552.00K |
| Depreciation & Amortization | 843.00K | 2.04M | 1.72M | 1.73M | 2.03M | 975.00K | 750.00K | 802.00K | 1.04M | 864.00K |
| EBITDA | -235.06M | 39.84M | -5.16M | -65.59M | -51.80M | -62.87M | -63.37M | -34.16M | -23.18M | -11.46M |
| EBITDA Ratio | -903.95% | 14.58% | -3.91% | -337.40% | -755.25% | -7,092.69% | -30,451.21% | -419.00% | -403.59% | -377.11% |
| Operating Income | -86.42M | 14.54M | -4.60M | -56.82M | -52.46M | -65.02M | -63.78M | -34.67M | -25.30M | -15.40M |
| Operating Income Ratio | -332.32% | 13.12% | -5.40% | -342.36% | -785.61% | -7,200.66% | -30,813.53% | -428.92% | -420.96% | -506.55% |
| Total Other Income/Expenses | -152.29M | 20.23M | -5.12M | -12.06M | -2.90M | -314.00K | -1.54M | -1.54M | 130.00K | 2.52M |
| Income Before Tax | -238.71M | 34.77M | -9.72M | -68.88M | -55.35M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Income Before Tax Ratio | -917.97% | 31.39% | -11.43% | -414.99% | -828.97% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| Income Tax Expense | -19.00M | -609.00K | 15.97M | 1.65M | 1.86M | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -219.71M | 35.38M | -25.69M | -68.88M | -55.35M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Net Income Ratio | -844.91% | 31.94% | -30.19% | -414.99% | -828.97% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| EPS | -42.49 | 7.33 | -6.74 | -20.42 | -36.46 | -87.55 | -95.94 | -103.52 | -40.50 | -38.17 |
| EPS Diluted | -42.49 | 2.98 | -6.74 | -20.42 | -36.46 | -87.55 | -95.94 | -103.52 | -40.50 | -38.17 |
| Weighted Avg Shares Out | 5.17M | 4.83M | 3.81M | 3.37M | 1.52M | 746.31K | 680.83K | 349.80K | 621.65K | 428.95K |
| Weighted Avg Shares Out (Dil) | 5.17M | 4.86M | 3.81M | 3.37M | 1.52M | 746.31K | 680.83K | 349.80K | 621.65K | 428.95K |
Cartesian Therapeutics Announces New Employment Inducement Grants
Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
Cartesian Therapeutics, Inc. (RNAC) Loses -24.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports